Spain· ES:1171192001
BRINEURA 150 MG SOLUCION PARA PERFUSION
A medicinal product containing cerliponasa alfa, registered in Spain by Biomarin International Limited.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- cerliponasa alfa
- Manufacturer
- Biomarin International Limited
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cerliponasa alfa in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBrineura 150 mgBioMarin International
- CzechiaBRINEURABioMarin International Limited, Dublin
- FinlandBrineuraBiomarin International Limited
- FranceBRINEURA 150 mg, solution pour perfusionBIOMARIN INTERNATIONAL LIMITED (IRLANDE)
- IrelandBrineura 150 mg solution for infusionBioMarin International Limited
- IcelandBrineuraBioMarin International Limited
- NetherlandsBrineura 150 mg oplossing voor infusieBioMarin International Limited
- SwedenBrineura 150 mg Infusionsvätska, lösningBioMarin International Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brineura
- Liechtenstein · Brineura
- Norway · Brineura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a60ead01-e67e-41ea-9fe6-c3dba672b68b GET /v1/drugs/a60ead01-e67e-41ea-9fe6-c3dba672b68b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1561121205000}",
"nregistro": "1171192001",
"substance": "cerliponasa alfa"
}See everything about cerliponasa alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.